Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)

被引：0

作者：

Samuel, David ^{[1
]}

Martin, Thomas ^{[2
]}

Wang, Michael

Vij, Ravi ^{[4
]}

Jakubowiak, Andrzej J. ^{[5
]}

Jagannath, Sundar ^{[6
]}

Lonial, Sagar ^{[7
]}

Kukreti, Vishal ^{[8
]}

Bahlis, Nizar J. ^{[9
]}

Alsina, Melissa ^{[10
]}

Chanan-Khan, Asher A. ^{[11
]}

Somlo, George ^{[12
]}

Buadi, Francis ^{[13
]}

Reu, Frederic J. ^{[14
]}

Zonder, Jeffrey A. ^{[15
]}

Song, Kevin ^{[16
]}

Stadtmauer, Edward ^{[17
]}

Wong, Alvin F. ^{[18
]}

Vallone, Marcy ^{[18
]}

Chang, Yu-Lin ^{[18
]}

Kauffman, Michael ^{[18
]}

Orlowski, Robert Z. ^{[3
]}

Stewart, A. Keith ^{[19
]}

Singhal, Seema B. ^{[20
]}

机构：

[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[2] Univ San Francisco, San Francisco, CA 94117 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

[4] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA

[5] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[6] Mt Sinai Med Ctr, Multiple Myeloma Program, New York, NY 10029 USA

[7] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[8] Princess Margaret Hosp, Div Hematol Oncol, Toronto, ON M4X 1K9, Canada

[9] Univ Calgary, Div Hematol, Calgary, AB, Canada

[10] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

[11] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[12] City Hope Natl Med Ctr, Duarte, CA 91010 USA

[13] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA

[14] Taussig Canc Ctr, Cleveland, OH USA

[15] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[16] Univ British Columbia, Div Hematol & Leukemia BMT, Vancouver, BC V5Z 1M9, Canada

[17] Univ Penn, Philadelphia, PA 19104 USA

[18] Onyx Pharmaceut, Emeryville, CA USA

[19] Mayo Clin Arizona, Scottsdale, AZ USA

[20] Northwestern Univ, Feinberg Sch Med, Div Hem Onc, Chicago, IL USA

[21] Multiple Myeloma Res Consortium, Norwalk, CT USA

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

下载

页码：433 / 433

页数：1

共 50 条

[31] Pharmacokinetics (PK) and safety of carfilzomib (CFZ) in patients (Pts) with advanced malignancies and varying degrees of hepatic impairment (HI): an open-label, single-arm, phase 1 study
Brown, J.
Plummer, R.
Bauer, T. M.
Anthony, S.
Sarantopoulos, J.
De Vos, F.
White, M.
Schupp, M.
Ou, Y.
Vaishampayan, U.
ANNALS OF ONCOLOGY, 2016, 27
[32] Jaktinib in patients (pts) with myelofibrosis (MF) who were refractory to or relapsed after ruxolitinib: A single-arm, open-label, multicenter, phase 2 study
Jin, Jie
Zhang, Yi
Zhang, Qike
Liu, Qingchi
Zhou, Hu
Gao, Sujun
Wang, Wei
Dang, Huibing
Chen, Yuqing
Wang, Jishi
Zhao, Peng
Yang, Haiping
Ma, Liangming
Zhao, Qingwei
Suo, Shanshan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[33] An Open-Label, Single-Arm, Phase 1 Study of the Pharmacokinetics (PK) and Safety of Carfilzomib in Patients with Relapsed Multiple Myeloma and End-Stage Renal Disease (ESRD)
Quach, Hang
White, Darrell
Spencer, Andrew
Ho, P. Joy
Bhutani, Divaya
White, Mike
Inamdar, Sandeep
Morris, Chris
Ou, Ying
Gyger, Martin
BLOOD, 2016, 128 (22)
[34] SINGLE-AGENT CARFILZOMIB VERSUS A BEST SUPPORTIVE CARE REGIMEN IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: FOCUS (PX-171-011), A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY
Hajek, R.
HAEMATOLOGICA, 2012, 97 : 614 - 615
[35] Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Morschhauser, Franck
Tilly, Herve
Chaidos, Aristeidis
McKay, Pamela
Phillips, Tycel
Assouline, Sarit
Batievi, Connie Lee
Campbell, Phillip
Ribrag, Vincent
Damaj, Gandhi Laurent
Dickinson, Michael
Jurczak, Wojciech
Kazmierczak, Maciej
Opat, Stephen
Radford, John
Schmitt, Anna
Yang, Jay
Whalen, Jennifer
Agarwal, Shefali
Adib, Deyaa
Salles, Gilles
LANCET ONCOLOGY, 2020, 21 (11): : 1433 - 1442
[36] RESPONSES TO SINGLE-AGENT CARFILZOMIB (CFZ) ARE NOT AFFECTED BY CYTOGENETICS IN PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (R/R MM)
Jakubowiak, A. J.
Martin, T.
Singhal, S.
Wang, M.
Vij, R.
Jagannath, S.
Lonial, S.
Kukreti, V.
Buadi, F.
Kunkel, L.
Bray, L.
Vallone, M.
Orlowski, R. Z.
Siegel, D. S.
ANNALS OF ONCOLOGY, 2011, 22 : 122 - 122
[37] Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study
You, Liangshun
Liu, Yi
Mai, Wenyuan
Xie, Wanzhuo
Zhou, De
Mao, Liping
Chen, Lili
Zhou, Xinping
Ma, Liya
Zheng, Xiaolong
Wei, Juying
Lou, Yinjun
Ye, Xingnong
Tong, Hongyan
Jin, Jie
Meng, Haitao
EUROPEAN JOURNAL OF CANCER, 2024, 202
[38] Everolimus for Relapsed/Refractory Classical Hodgkin Lymphoma: Multicenter, Open-Label, Single-Arm, Phase 2 Study
Johnston, Patrick B.
Pinter-Brown, Lauren
Rogerio, Jaqueline
Warsi, Ghulam
Chau, Quincy
Ramchandren, Radhakrishnan
BLOOD, 2012, 120 (21)
[39] Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study
Quach, Hang
White, Darrell
Spencer, Andrew
Ho, P. Joy
Bhutani, Divaya
White, Mike
Inamdar, Sandeep
Morris, Chris
Ou, Ying
Gyger, Martin
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (06) : 1067 - 1076
[40] Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study
Hang Quach
Darrell White
Andrew Spencer
P. Joy Ho
Divaya Bhutani
Mike White
Sandeep Inamdar
Chris Morris
Ying Ou
Martin Gyger
Cancer Chemotherapy and Pharmacology, 2017, 79 : 1067 - 1076

← 1 2 3 4 5 →